- Home
- JHI vs KPTI Comparison
JHI vs KPTI Comparison
Compare JHI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- KPTI
- Stock Information
- Founded
- JHI 1971
- KPTI 2008
- Country
- JHI United States
- KPTI United States
- Employees
- JHI N/A
- KPTI N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- KPTI Health Care
- Exchange
- JHI Nasdaq
- KPTI Nasdaq
- Market Cap
- JHI 124.0M
- KPTI 109.9M
- IPO Year
- JHI N/A
- KPTI 2013
- Fundamental
- Price
- JHI $14.07
- KPTI $0.78
- Analyst Decision
- JHI
- KPTI Strong Buy
- Analyst Count
- JHI 0
- KPTI 4
- Target Price
- JHI N/A
- KPTI $5.00
- AVG Volume (30 Days)
- JHI 29.5K
- KPTI 1.1M
- Earning Date
- JHI 01-01-0001
- KPTI 11-05-2024
- Dividend Yield
- JHI 6.80%
- KPTI N/A
- EPS Growth
- JHI N/A
- KPTI N/A
- EPS
- JHI 1.05
- KPTI N/A
- Revenue
- JHI N/A
- KPTI $148,442,000.00
- Revenue This Year
- JHI N/A
- KPTI $6.67
- Revenue Next Year
- JHI N/A
- KPTI $8.58
- P/E Ratio
- JHI $12.47
- KPTI N/A
- Revenue Growth
- JHI N/A
- KPTI 1.77
- 52 Week Low
- JHI $11.63
- KPTI $0.62
- 52 Week High
- JHI $13.40
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- JHI 46.43
- KPTI 41.33
- Support Level
- JHI $14.05
- KPTI $0.75
- Resistance Level
- JHI $14.13
- KPTI $0.95
- Average True Range (ATR)
- JHI 0.12
- KPTI 0.06
- MACD
- JHI -0.02
- KPTI -0.02
- Stochastic Oscillator
- JHI 21.87
- KPTI 12.93
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.